# Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study

> **NCT07257068** · NA · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 14 (estimated)

## Conditions studied

- Checkpoint Inhibitor
- Pilot Study
- Diabetes Melletus

## Interventions

- **OTHER:** Infliximab

## Key facts

- **NCT ID:** NCT07257068
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07257068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07257068, "Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07257068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*